HCW Biologics Inc. (NASDAQ:HCWB - Get Free Report) Director Scott Garrett acquired 7,736 shares of the stock in a transaction on Wednesday, July 29th. The stock was bought at an average price of $2.58 per share, with a total value of $19,958.88. Following the completion of the acquisition, the director directly owned 41,644 shares of the company's stock, valued at $107,441.52. This trade represents a 22.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
HCW Biologics Stock Performance
Shares of NASDAQ:HCWB opened at $3.20 on Friday. HCW Biologics Inc. has a 52-week low of $1.50 and a 52-week high of $44.10. The firm has a market capitalization of $5.12 million, a P/E ratio of -0.06 and a beta of 2.29. The stock has a 50 day moving average price of $6.50 and a 200-day moving average price of $5.20.
HCW Biologics (NASDAQ:HCWB - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of ($2.64) by $3.01. The company had revenue of $6.54 million for the quarter, compared to analyst estimates of $6.54 million. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.
Analysts Set New Price Targets
A number of brokerages recently weighed in on HCWB. Wall Street Zen upgraded shares of HCW Biologics to a "hold" rating in a report on Saturday, May 23rd. Maxim Group lifted their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, May 28th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of HCW Biologics in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $30.00.
View Our Latest Report on HCW Biologics
Hedge Funds Weigh In On HCW Biologics
A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new position in HCW Biologics Inc. (NASDAQ:HCWB - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,180 shares of the company's stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent reporting period. Institutional investors and hedge funds own 2.96% of the company's stock.
About HCW Biologics
(
Get Free Report)
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
